Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $8.76 Million - $11.5 Million
-155,670 Reduced 92.79%
12,093 $835,000
Q3 2023

Nov 14, 2023

SELL
$65.94 - $99.04 $2.91 Million - $4.37 Million
-44,170 Reduced 20.84%
167,763 $11.4 Million
Q2 2023

May 17, 2024

BUY
$62.68 - $95.05 $12.5 Million - $19 Million
199,840 Added 1652.53%
211,933 $19.9 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $4.26 Million - $6.46 Million
67,949 Added 47.19%
211,933 $19.9 Million
Q1 2023

May 17, 2024

BUY
$47.19 - $70.77 $1.56 Million - $2.33 Million
32,953 Added 29.68%
143,984 $9.76 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $1.56 Million - $2.33 Million
32,953 Added 29.68%
143,984 $9.76 Million
Q4 2022

May 17, 2024

BUY
$30.35 - $53.15 $3 Million - $5.26 Million
98,938 Added 818.14%
111,031 $5.5 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $3.37 Million - $5.9 Million
111,031 New
111,031 $5.5 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $5.32 Million - $7.39 Million
-73,421 Reduced 75.68%
23,596 $1.84 Million
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $264,944 - $364,210
-2,936 Reduced 2.94%
97,017 $9.26 Million
Q2 2021

Aug 16, 2021

BUY
$93.66 - $139.27 $1.24 Million - $1.84 Million
13,215 Added 15.24%
99,953 $12.4 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $10.1 Million - $13.4 Million
86,738 New
86,738 $11.4 Million
Q3 2019

Nov 14, 2019

SELL
$90.37 - $122.49 $1.21 Million - $1.64 Million
-13,419 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $1.2 Million - $1.58 Million
13,419 New
13,419 $1.58 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Portfolio

Follow Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.